A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs Cannabidiol (Primary) ; Vigabatrin
- Indications Infantile spasms
- Focus Registrational; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 02 Mar 2018 According to an INSYS Therapeutics media release, status changed from not yet recruiting to recruiting.
- 01 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
- 07 Feb 2018 New trial record